Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published 8 August 2008 Volume 2008:4(4) Pages 821—826


Review by Single-blind

Peer reviewer comments 3

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Acanthamoeba encystment: multifactorial effects of buffers, biocides, and demulcents present in contact lens care solutions

Kovacs CJ, Lynch SC, Rah MJ, Millard KA, Morris TW

Clinical Ophthalmology 2015, 9:1905-1913

Published Date: 13 October 2015

Paraplegia after intercostal neurolysis with phenol

Gollapalli L, Muppuri R

Journal of Pain Research 2014, 7:665-668

Published Date: 20 November 2014

Iatrogenic disease in the elderly: risk factors, consequences, and prevention

Sompol Permpongkosol

Clinical Interventions in Aging 2011, 6:77-82

Published Date: 21 March 2011

The western diet and lifestyle and diseases of civilization

Pedro Carrera-Bastos, Maelan Fontes-Villalba, James H O’Keefe, et al

Research Reports in Clinical Cardiology 2011, 2:15-35

Published Date: 9 March 2011

Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo)

Marco Matteo Ciccone, Ambrogio Aquilino, Francesca Cortese, et al

Vascular Health and Risk Management 2010, 6:297-305

Published Date: 28 April 2010

Chronomics, human time estimation, and aging

Franz Halberg, Robert B Sothern, Germaine Cornélissen, Jerzy Czaplicki

Clinical Interventions in Aging 2008, 3:749-760

Published Date: 5 December 2008

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

The role of duloxetine in the treatment of anxiety disorders

Domenico De Berardis, Nicola Serroni, Alessandro Carano, Marco Scali, Alessandro Valchera, et al

Neuropsychiatric Disease and Treatment 2008, 4:929-935

Published Date: 10 October 2008